Lymphoma

The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.

Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.

Septic shock remained significantly associated with increased 28-day mortality among patients with hematologic malignancies, according to study results published in Journal of the National Comprehensive Cancer Network.

Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

The addition of brentuximab vedotin to front-line chemotherapy reduced risk for death by 41% among patients with newly diagnosed advanced classical Hodgkin lymphoma, according to topline data released by the agent’s manufacturer.

The FDA is investigating a possible increased mortality risk with umbralisib, approved in the United States for treatment of two types of lymphoma.

The FDA updated the prescribing information for axicabtagene ciloleucel to allow the use of prophylactic corticosteroids to manage the severity of certain treatment-related adverse events.